Australia markets closed

Bellicum Pharmaceuticals, Inc. (BLCM)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.2000-0.0247 (-11.01%)
At close: 03:04PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 1.94M
Enterprise value -44.21M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)4.09
Price/book (mrq)40.34
Enterprise value/revenue -29.32
Enterprise value/EBITDA 1.86

Trading information

Stock price history

Beta (5Y monthly) 1.59
52-week change 3-80.00%
S&P500 52-week change 316.55%
52-week high 31.5000
52-week low 30.0600
50-day moving average 30.2016
200-day moving average 30.3934

Share statistics

Avg vol (3-month) 318.6k
Avg vol (10-day) 320.24k
Shares outstanding 59.72M
Implied shares outstanding 612.15M
Float 86.28M
% held by insiders 11.23%
% held by institutions 125.05%
Shares short (14 May 2023) 41.44M
Short ratio (14 May 2023) 40.17
Short % of float (14 May 2023) 417.08%
Short % of shares outstanding (14 May 2023) 415.15%
Shares short (prior month 13 Apr 2023) 491k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 305 Feb 2020
Ex-dividend date 4N/A
Last split factor 21:10
Last split date 305 Feb 2020

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 Sept 2023


Profit margin 0.00%
Operating margin (ttm)-77.40%

Management effectiveness

Return on assets (ttm)-78.10%
Return on equity (ttm)-148.50%

Income statement

Revenue (ttm)1.51M
Revenue per share (ttm)0.05
Quarterly revenue growth (yoy)0.00%
Gross profit (ttm)N/A
EBITDA -23.82M
Net income avi to common (ttm)-22.38M
Diluted EPS (ttm)-0.7200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)5.91M
Total cash per share (mrq)0.61
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)3.05
Book value per share (mrq)-2.78

Cash flow statement

Operating cash flow (ttm)-22.85M
Levered free cash flow (ttm)-15.37M